|
US2019218184A1
|
|
Crystalline form of lenvantinib mesylate and process of preparation thereof
|
|
CN111094290A
|
|
Crystal form of mono succinate of Ribociclib, preparation method and application thereof
|
|
US2018282342A1
|
|
Salt of pyrrolo[2,3-D]pyrimidine compound and novel polymorph of salt
|
|
US2019322646A1
|
|
Crystalline forms of AP26113, and preparation method thereof
|
|
WO2018059531A1
|
|
Crystal form of adenosine a2a receptor antagonist drug and preparation method and use thereof
|
|
EP3434675A1
|
|
Hydrochloride salt crystal of drug for treating or preventing jak-associated disease and preparation method thereof
|
|
WO2017152858A1
|
|
Crystal form of ceritinib and preparation method thereof
|
|
US2019092756A1
|
|
Crystalline form a of 2-[(2r)-2-methyl-2-pyrrolidyl]-1h-benzimidazole-7-carboxamide dihydrochloride and preparation method thereof
|
|
CN106831620A
|
|
Crystal formation of Lei Xina get and preparation method thereof
|
|
US2019055255A1
|
|
Crystalline forms of (6-(1H-indazol-6-yl)-N-[4-(4-(4-morpholinyl)phenyl]imidazo[1,2-A]pyrazin-8-amine) methanesulfonate
|
|
WO2017114446A1
|
|
New crystal form of eluxadoline and preparation method thereof
|
|
MX2018007887A
|
|
Novel crystalline form of selective s1p1 receptor agonist and method for preparing same.
|
|
WO2017088812A1
|
|
Composition and eutectic of saxagliptin and metformin, and preparation method and use thereof
|
|
WO2017076358A1
|
|
New crystal form of imidazolyl biphenyl compound salt and preparation method thereof
|
|
WO2017076356A1
|
|
Novel crystal form of flibaserin, and preparation method therefor
|
|
WO2017067506A1
|
|
Novel crystalline form of palbociclib
|
|
WO2017063572A1
|
|
Novel crystal form of cell apoptosis inducing agent and preparation method thereof
|
|
WO2017032281A1
|
|
Novel crystal forms of panobinostat lactate
|
|
WO2017016512A1
|
|
New crystalline form of masitinib mesylate and preparation method therefor
|
|
WO2016206619A1
|
|
Novel crystalline forms of volasertib and trihydrochloride thereof
|
